

# Evofosfamide

Catalog No: tcsc0616



## Available Sizes

---

**Size:** 2mg

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

---

**CAS No:**

918633-87-1

**Formula:**

$C_9H_{16}Br_2N_5O_4P$

**Pathway:**

Others

**Target:**

Others

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 94 mg/mL (209.34 mM; Need ultrasonic and warming)

**Alternative Names:**

TH-302

**Observed Molecular Weight:**

449.04


**Product Description**

Evofosfamide (TH-302) is a **hypoxia**-activated prodrug with **IC<sub>50</sub>** of 10  $\mu$ M and 1000  $\mu$ M in hypoxia (N<sub>2</sub>) and normoxia (21% O<sub>2</sub>), respectively.

IC50 & Target: Hypoxia-activated prodrug<sup>[1]</sup>

**In Vitro:** Evofosfamide (TH-302) induces  $\gamma$ H2AX and apoptosis. Evofosfamide displays hypoxia-selective and concentration-dependent cytotoxic activity that is comparable in both p53-proficient and -deficient cells. Treatment with Evofosfamide (TH-302) alone causes an accumulation of G<sub>2</sub>/M cells. Inhibition of Chk1 by PF47736 in cells treated with Evofosfamide reduces Evofosfamide (TH-302)-mediated G<sub>2</sub>/M arrest under both normoxia and hypoxia<sup>[1]</sup>.

**In Vivo:** Evofosfamide (TH-302) is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. The mean values of normalized K<sup>trans</sup> decrease 69.2% for Evofosfamide (TH-302)-treated mice in Hs766t tumors, decrease 46.1% for Mia PaCa-2 tumors and increase 4.9% in SU.86.86 tumors. Both changes for Hs766t and Mia PaCa-2 treatment groups are statistically significant (P[2]. A significant reduction in the hypoxic fraction (HF) to 2.1% $\pm$ 4.7% is seen after 95% oxygen breathing (P2)<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!